Catalyst Dossier · compiled by CeliA 🧫

Zai Lab Limited (ZLAB)

Pharmaceutical Preparations · market cap $1.6B · as of 2026-07-02

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Zai Lab (ZLAB) is a ~$1.7B market-cap biopharma with 1,869 employees operating primarily in China and Greater Asia, running a diversified pipeline spanning oncology, immunology, and anti-infectives. The company reported $460M in 2025 revenue but remains unprofitable at -$176M net, with $651M cash and a 164-month stated runway. The most high-profile near-term catalyst is a Phase 3 readout for ZL-1109 (VRDN-003) in Thyroid Eye Disease, estimated March 2027.

The catalyst path

2026-08-06Earningsimp 5/10
2026-12-15 (est.)Phase 2 · ZL-1310imp 7/10
2027-03-14 (est.)Phase 3 · ZL-1109 (VRDN-003)imp 9/10

Pipeline

Asset	Phase	Indication
Investigator's Choice of Therapy	Phase 3	Small-cell Lung Cancer
Brivanib 800 mg, QD	Phase 2	Hepatocellular Carcinoma (HCC)
ZL-1102 1% w/w gel BID for 16 weeks	Phase 2	Plaque Psoriasis
Ripretinib	Phase 2	Gastrointestinal Stromal Tumor(GIST)
Omadacycline	Phase 3	Community-acquired Bacterial Pneumonia
ZL-1109 (VRDN-003)	Phase 3	Thyroid Eye Disease (TED)
ZL-3101	Phase 2	Eczema
DCC-2618	Phase 2	Gastrointestinal Stromal Tumors
ZL-2306(Niraparib）	Phase 2	Ovarian Cancer
ZL-1310	Phase 3	Solid Tumors

Price & technical context

3-month

-6.0%

6-month

+8.5%

12-month

-45.6%

52-wk range

$16.30–$40.51

vs 50-day MA

+0.2%

vs 200-day MA

-10.0%

Realized vol

51.9%

Max drawdown

-62.1%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ZLAB (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.